Business Wire

Eastdil Secured Announces Definitive Agreement for Management-Led Recapitalization, in Partnership with Temasek and Clients of Guggenheim Investments, Solidifying Position as Premier Private Independent Real Estate Investment Bank

Share

Eastdil Secured, LLC (“Eastdil Secured” or the “firm”), the original, premier private real estate investment banking company, today announced it has entered into a definitive agreement on a management-led recapitalization in partnership with Temasek, a global investment company headquartered in Singapore, and certain institutional clients of Guggenheim Investments. Following the sale, which is expected to be completed by the fourth quarter of 2019, the firm will be privately held, and Wells Fargo & Company (“Wells Fargo”), Eastdil Secured’s current owner, will retain a minority ownership interest and maintain the public market investment bankers, who will transition to Wells Fargo’s Corporate & Investment Banking division. The firm will maintain its name and continue to be led by Benjamin V. Lambert as Chairman, Roy Hilton March as Chief Executive Officer, D. Michael Van Konynenburg as President, as well as its current Management Committee. The terms of the transaction were not disclosed.

With a record of successfully advising clients on the largest, most relevant real estate transactions, Eastdil Secured holds the top market share for 2018 and year to date 2019 for real estate deals greater than $100 million across all property types in the United States. In 2018, Eastdil Secured advised on 827 transactions for $243.5 billion. In partnership with Guggenheim Investments and Temasek, Eastdil Secured will be positioned to further enhance its leading role in the U.S. commercial real estate capital markets, while also strengthening its growing presence in both Europe and Asia.

“We are excited to embark on this next chapter of Eastdil Secured’s evolution,” said Benjamin V. Lambert, Chairman of Eastdil Secured. “With our new long-term partners, we will continue to be the leader in our industry by providing our clients with a unique combination of real estate and capital markets expertise.”

Roy Hilton March, Chief Executive Officer of Eastdil Secured, said, “Guggenheim Investments, on behalf of certain institutional clients, and Temasek represent ideal partners for Eastdil Secured as we embark on this next stage of growth. The eagerness of our professionals to acquire a meaningful stake in the future of Eastdil Secured, alongside these preeminent investors, underscores our shared confidence in our firm’s people and future. Most importantly, through this transaction, we will be better able to serve our clients with investments in enhanced technology, a broader footprint and deeper global relationships. Ultimately, our new ownership structure will allow us to continue providing truly independent, global advice and ensure our clients receive differentiated guidance in an increasingly competitive market.”

D. Michael Van Konynenburg, President of Eastdil Secured, added, “In today’s environment, clients need a trusted advisor that prioritizes their goals, not the commissions of any individual, and this is what has and will continue to set Eastdil Secured apart. We will continue to execute the most impactful deals that advance our clients’ objectives, and we look forward to capitalizing on our new partners’ substantial networks and global insight.”

The firm will continue to have its U.S. headquarters in New York City and Los Angeles and its Europe headquarters in London, with additional domestic offices in Atlanta, Boston, Chicago, Dallas, Orange County, San Francisco, Seattle, Silicon Valley and Washington D.C., and additional international offices in Dubai, Frankfurt, Hong Kong and Tokyo. Eastdil Secured is the only firm with a team dedicated to raising capital and placing deals in Asia and the Middle East. Eastdil Secured will continue to leverage its global presence to provide clients with connectivity between the largest and most active real estate investors and lenders in the world.

About Eastdil Secured

Eastdil Secured is the original, premier private real estate investment banking company with the mission to create value for our clients through creative, actionable ideas and flawless execution, and to be the most relevant and trusted advisor in the commercial real estate capital markets. Eastdil Secured has built its expertise into a knowledge franchise that is recognized as the dominant force in commercial real estate and investment banking by private investors and institutions alike. Its unrivaled combination of capital markets know-how and in-depth understanding of real estate fundamentals allows the firm to deliver on its promises in order to meet the precise needs of its clients.

Contact information

Media:
Joele Frank, Wilkinson Brimmer Katcher
Jonathan Keehner / Andrew Siegel / Jillian Kary
212-355-4449

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

ESMO 2020: Cabometyx ® (cabozantinib) in Combination With Opdivo ® (nivolumab) Demonstrates Significant Survival Benefits in Patients With Advanced Renal Cell Carcinoma in Pivotal Phase III CheckMate -9ER Trial19.9.2020 18:30:00 CESTPress release

Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced the first presentation of results from the pivotal Phase III CheckMate -9ER trial, in which Cabometyx® (cabozantinib) in combination with Bristol Myers Squibb’s Opdivo® (nivolumab) demonstrated significant improvements across all efficacy endpoints, including overall survival (OS), in previously untreated advanced renal cell carcinoma (RCC).1 Cabometyx® in combination with Opdivo® reduced the risk of death by 40% versus sunitinib (HR: 0.60 [98.89% Confidence Interval [CI]: 0.40–0.89]; p= 0.0010; median OS not reached in either arm). In patients receiving Cabometyx® in combination with Opdivo®, median progression-free survival (PFS), the trial’s primary endpoint, was doubled compared to those receiving sunitinib alone: 16.6 months versus 8.3 months respectively (Hazard Ratio [HR]: 0.51 [95% CI 0.41–0.64], p < 0.0001). In addition, Cabometyx® in combination with Opdivo® demonstrated a superior objective response rate, wit

Takeda Presents New Data Highlighting Scientific Advancements in Lung Cancer at ESMO Virtual Congress18.9.2020 12:55:00 CESTPress release

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the company is presenting data from its lung cancer portfolio at the virtual European Society for Medical Oncology (ESMO) conference. Notably, insights from sub-analyses of the Phase 3 ALTA 1L study reinforce both the compelling evidence of intracranial efficacy with ALUNBRIG® (brigatinib) as a first-line treatment for patients with anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) as well as associated quality of life (QoL) data. Takeda is also featuring updated 10-month follow-up results from the Phase 1/2 trial of mobocertinib (TAK-788), demonstrating mobocertinib achieved a duration of response (DoR) of more than one year in the trial’s study population of patients with epidermal growth factor receptor (EGFR) Exon20 insertion+ metastatic NSCLC (mNSCLC). “We’re pleased to present our ongoing research in lung cancer at this year’s virtual ESMO congress, including new

Incyte Announces Encouraging Results From Phase 2 Trial of Retifanlimab (INCMGA0012) in Patients With Previously Treated, Advanced Squamous Cell Carcinoma of the Anal Canal18.9.2020 12:00:00 CESTPress release

Incyte (Nasdaq:INCY) today announced results from its Phase 2 POD1UM-202 trial evaluating retifanlimab, a PD-1 inhibitor, in previously treated patients with advanced squamous cell carcinoma of the anal canal (SCAC) who have progressed following standard platinum-based chemotherapy. The trial enrolled 94 patients, including those with well-controlled human immunodeficiency virus (HIV) infection (10%). Retifanlimab monotherapy resulted in a confirmed objective response rate (ORR) of 14% as determined by independent central review (ICR) using RECIST v1.1. Responses were observed regardless of PD-L1 status, presence of liver metastases, age or HIV+ status. Retifanlimab was generally well-tolerated with a safety profile as expected of a PD-1 inhibitor and no loss of HIV infection control. Key findings from POD1UM-202: N=94 ORR* (95% CI) 13.8% (7.6-22.5) Best OR*, n 1 CR 12 PR 33 SD DCR 48.9% DOR, median (95% CI), months 9.5 (5.6-NE) PFS, median (95% CI), months 2.3 (1.9-3.6) OS, median (95

Sigfox and Cube Infrastructure Managers Announce Major Partnership in IoT Infrastructure18.9.2020 09:30:00 CESTPress release

Sigfox, the global 0G network1 and cloud provider for industrial data, is proud to announce a new strategic alliance with Cube Infrastructure Managers (Cube), through the sale of its German 0G network to Cube. Sigfox has grown its 0G IoT services by rolling out 0G networks across 72 countries and regions, which was largely achieved with partners called Sigfox Operators. These operators are the owners of the 0G networks, which they operate as exclusive connectivity providers of Sigfox IoT services, offering worldwide connectivity to customers. The sale of the German network to Cube will allow Sigfox to finance its continued innovation efforts in data value extraction and improvements in cloud algorithms to reduce energy consumption and allow the implementation of even more cost-effective devices and sensors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200918005116/en/ Cube Infrastructure Managers, the European infrastructu

Sensorion successfully raises approximately €31 (US$ 36.5) million in an oversubscribed private placement to US and European investors18.9.2020 08:00:00 CESTPress release

Regulatory News: Not for release, publication or distribution, directly or indirectly, in or into the United States, Canada, Australia or Japan. This press release is not intended as an offer and is for informational purpose only Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN – the “Company”) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders announces today the success of its previously announced capital increase. The Company has placed 18,236,000 new ordinary shares with a nominal value of €0.10 each (the “New Shares”), for total gross proceeds of approximately € 31 million by means of an accelerated bookbuild offering to the benefit of categories of persons (the “Reserved Offering”). The issue price of the New Shares is €1.70 per share, representing a 3.5% discount to the weighted average share price on the day preceding the date on which the issuance price

Vifor Pharma Group Announces Successful Sale of OM Pharma18.9.2020 07:00:00 CESTPress release

Regulatory News: Vifor Pharma has today announced the successful sale of 100% of the share capital of OM Pharma, a Vifor Pharma Group company to Optimus Holding Ltd. The terms of the deal include: A purchase consideration of MCHF 435 for 100% of the share capital An earn out related to potential future value gains on 20% of Optimus Holding Ltd. equity to be determined before the end of 2027 upon a trade sale, IPO or EBITDA multiple This earn out together with the purchase consideration could result in a total transaction value exceeding MCHF 500. The deal is expected to close within 30 days. OM Pharma is a Geneva-based company mainly active in the field of microbial derived immunotherapeutics and has developed strongly outside the core strategy of Vifor Pharma over the past few years. Optimus Holding Ltd. is a Swiss Group, founded by Etienne Jornod together with long-standing Swiss entrepreneurs and Abdi Ibrahim (28.5%), a Turkey-based pharmaceutical company operating in 12 countries a